Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
The Motley Fool November 4, 2004 Tom Taulli	Greenfield Prints Greenbacks Greenfield's IPO was overshadowed by the Google offering. Yet, the leading provider of survey solutions appears to be ideal for the Net.
The Motley Fool April 26, 2007 Tom Taulli	Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth.
The Motley Fool April 5, 2011 Frank Vinluan	Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat.
The Motley Fool February 4, 2010 Brian Orelli	A Drugless Drugmaker IPO! Biotech investors embrace risk ... sort of. The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market.
The Motley Fool December 31, 2010 Brian Orelli	3 Biotech 2010 IPOs Worthy of a Look These IPOs are worth a spot on your watchlist.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool February 22, 2006 Stephen D. Simpson	Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
The Motley Fool August 19, 2010 Brian Orelli	High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS.
Bio-IT World August 13, 2002 Mark D. Uehling	Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way?
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool August 23, 2004 Bill Mann	Google: The Scorecard The most anticipated IPO in history has passed. After all the hype and garment rending, how'd it go?
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
The Motley Fool June 5, 2009 Brian Orelli	Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients.
The Motley Fool December 19, 2008 Brian Orelli	Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool March 13, 2007 Brian Lawler	Panacos Springs Ahead Panacos advances its lead drug program.
The Motley Fool March 15, 2005 Lawrence Meyers	Pharma's Outsourcing Elixir Pharmaceutical Product Development saves the drug companies money. Solid financials suggest it's a prescription that's working. Investors who do their due diligence may also find a few dollars earned in their brokerage accounts as well.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
InternetNews January 23, 2004 Michael Singer	Oracle Makes a Play for Life Sciences The business software giant acquires SiteWorks Solutions to capitalize on drug companies that need to run clinical trials.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
Bio-IT World October 2005 Mark D. Uehling	Phase Forward Acquires Lincoln Technologies As the most intriguing clinical trial technology deal of the year, the acquisition demonstrates both Phase Forward's financial resources and the appeal of Lincoln Technologies' Java- and Web-based tools for the analysis and visualization of drug safety.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool October 30, 2009 Brian Orelli	Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
InternetNews August 27, 2004 Paul Shread	Google Options Begin Trading Google began trading options on Friday, and interest in the financial instruments appeared strong... The Nasdaq rose 9 to 1862, the S&P 500 added 2 to 1107, and the Dow climbed 21 to 10,195... etc.
The Motley Fool September 25, 2007 Brian Orelli	No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
The Motley Fool April 29, 2004 Bob Bobala	Ready, Set, Google! The Internet darling finally filed for its IPO today, but investors should be cautious.
Bio-IT World April 2006 Michelle Zubatch	Value of Hosted Clinical Data Environments Instead of burning through venture capital, different levels of hosted clinical data management systems environments are available from clinical consulting vendors for efficiency-conscious clinical firms.
The Motley Fool August 10, 2004 Tom Taulli	Yahoo! the First Winner in Google IPO Yahoo!'s once-questioned acquisition of Overture appears to have been a huge coup. The company was clearly in a position of strength and was not shy in exacting a great deal.
InternetNews April 19, 2010	Oracle Grabs Health Software Firm Phase Forward In an all-cash deal, Oracle is shelling out $685 million to purchase Phase Forward, a Massachusetts-based firm specializing in software to manage drug data and health science.
The Motley Fool May 22, 2007 Mike Havrilla	Coley Gets a Cold Reception The market cares little for this drug developer's promising prospects, but some investors like this pharma at it current $230 million market cap, given the company's strong partnerships.
The Motley Fool October 1, 2009 Brian Orelli	Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock.
The Motley Fool June 23, 2004 Tom Taulli	The Google Way No doubt Google is calling the shots. Yet, not all investment banks are caving, as seen with this week's move by Merrill Lynch to opt out of the Google IPO.
Bio-IT World April 2006 Kevin Davies	Putting the IT in Clinical Trials A new report says that the clinical trials process must be reinvented to reverse the output decline of the pharmaceutical industry and meet the needs of its patients. That reinvention will be shaped by major advances in information technology.
Chemistry World October 15, 2013 Dinsa Sachan	Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed.
The Motley Fool May 29, 2009 Brian Orelli	This Company Is Hot and Going Places Pharma company sanofi-aventis licenses a program, including two phase 1 compounds from Exelixis.
The Motley Fool June 21, 2004 Brian Gorman	Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
The Motley Fool May 17, 2007 Mike Havrilla	Javelin Is Right on Target The company reformulates existing drugs to fill unmet needs, making its stock worthy of consideration.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
The Motley Fool September 11, 2007 Brian Orelli	A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note.